Kayvanpour, E.; Sedaghat-Hamedani, F.; Li, D.T.; Miersch, T.; Weis, T.; Hoefer, I.; Frey, N.; Meder, B.
Prognostic Value of Circulating Fibrosis Biomarkers in Dilated Cardiomyopathy (DCM): Insights into Clinical Outcomes. Biomolecules 2024, 14, 1137.
https://doi.org/10.3390/biom14091137
AMA Style
Kayvanpour E, Sedaghat-Hamedani F, Li DT, Miersch T, Weis T, Hoefer I, Frey N, Meder B.
Prognostic Value of Circulating Fibrosis Biomarkers in Dilated Cardiomyopathy (DCM): Insights into Clinical Outcomes. Biomolecules. 2024; 14(9):1137.
https://doi.org/10.3390/biom14091137
Chicago/Turabian Style
Kayvanpour, Elham, Farbod Sedaghat-Hamedani, Daniel Tian Li, Tobias Miersch, Tanja Weis, Imo Hoefer, Norbert Frey, and Benjamin Meder.
2024. "Prognostic Value of Circulating Fibrosis Biomarkers in Dilated Cardiomyopathy (DCM): Insights into Clinical Outcomes" Biomolecules 14, no. 9: 1137.
https://doi.org/10.3390/biom14091137
APA Style
Kayvanpour, E., Sedaghat-Hamedani, F., Li, D. T., Miersch, T., Weis, T., Hoefer, I., Frey, N., & Meder, B.
(2024). Prognostic Value of Circulating Fibrosis Biomarkers in Dilated Cardiomyopathy (DCM): Insights into Clinical Outcomes. Biomolecules, 14(9), 1137.
https://doi.org/10.3390/biom14091137